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O-glycosylation disorders pave the road for
understanding the complex human O-glycosylation
machinery
Walinka van Tol1,2, Hans Wessels2 and Dirk J Lefeber1,2
Over 100 human Congenital Disorders of Glycosylation (CDG)
have been described. Of these, about 30% reside in the O-
glycosylation pathway. O-glycosylation disorders are
characterized by a high phenotypic variability, reflecting the
large diversity of O-glycan structures. In contrast to N-
glycosylation disorders, a generic biochemical screening test is
lacking, which limits the identification of novel O-glycosylation
disorders. The emergence of next generation sequencing
(NGS) and O-glycoproteomics technologies have changed this
situation, resulting in significant progress to link disease
phenotypes with underlying biochemical mechanisms. Here,
we review the current knowledge on O-glycosylation disorders,
and discuss the biochemical lessons that we can learn on 1)
novel glycosyltransferases and metabolic pathways, 2) tissue-
specific O-glycosylation mechanisms, 3) O-glycosylation
targets and 4) structure-function relationships. Additionally, we
provide an outlook on how genetic disorders, O-
glycoproteomics and biochemical methods can be combined
to answer fundamental questions regarding O-glycan
synthesis, structure and function.
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Introduction
Glycosylation, the addition of carbohydrate chains to pro-
teins, is the most common post-translational and co-trans-
lational modification. It is initiated by the cytosolic
synthesis of activated sugars (with the exception of
CMP-N-acetylneuraminic acid) that are subsequently
transported to the endoplasmic reticulum (ER) and Golgi
apparatus, where glycans are assembled and modified on
proteins. Glycosylation affects many aspects of protein
function, including protein folding, enzyme activity and
cell-to-cell and cell-to-extracellular matrix (ECM) interac-
tions. Therefore, it is not surprising that glycosylation
disorders present with a broad range of clinical phenotypes.
Currently, over 100 different Congenital Disorders of Gly-
cosylation (CDG) have been described [1,2], the majority
affecting the N-glycosylation pathway. Broad availability of
an adequate screening assay for abnormal N-glycosylation,
isofocusing of serum transferrin (TIEF), has resulted in the
identification of defects in glycosyltransferases, nucleotide
sugar transporters and enzymes involved in sugar metabo-
lism, which are all directly linked to glycosylation. In recent
years, more complex mechanisms have been identified
underlying abnormal N-glycosylation related to Golgi traf-
ficking, homeostasis and vesicular transport [3,4,5].
In contrast to N-glycosylation defects, the identification of
O-glycosylation disorders is much more challenging. In
humans, O-glycans are initiated by seven different mono-
saccharides that can be further extended to complex O-
glycan structures. For mucin O-glycosylation (O-linked N-
acetylgalactosamine, O-GalNAc), the most common form
of O-glycosylation, over 20 polypeptide GalNAc trans-
ferases are known with tissue and substrate-specific activi-
ties [6,7]. Isofocusing of ApoC-III was developed to detect
defects in mucin type O-glycosylation [8]. Although many
of the Golgi homeostasis disorders showed abnormal mucin
type O-glycosylation of ApoC-III, only mutations in poly-
peptide GalNAc transferase 2 (GALNT2) could be detected
with this test. So far, the complexity of O-glycan structures
renders it impossible to design a single screening test for
diagnostics of O-glycosylation disorders.
O-glycans are important for protein structure, folding,
stability, recognition, expression, and processing, and
they are known to modulate enzyme activity
[9,10,11,12–15]. Furthermore, highly negatively charged
O-mucin glycans can bind water, forming protective
layers and preventing bacterial adhesion [16]. The func-
tion of an O-glycan can be tissue, protein, and site-
specific, alongside mediating different functions through-
out development [17]. That, O-glycans play not only
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important, but also complex roles, is illustrated by the vast
amount of O-glycan enzymes that upon knockout, caused
embryonic lethality or tissue-specific phenotypes in mice
[18,19]. Mice knockout systems have provided invalu-
able lessons about O-glycan function, for example, the
role of O-fucosylation of thrombospondin type 1 repeats
(TSRs) by POFUT2 in epithelial organization and
expression of signaling factors during gastrulation [20].
In humans, a more complete understanding of the human
O-glycosylation machinery can be accomplished by study-
ing genetic defects in O-glycosylation. Identification of an
increasing number of genetic O-glycosylation disorders
has been facilitated by the emergence of next generation
sequencing (NGS) [2]. Furthermore, recent develop-
ments in glycopeptide analysis revealed previously
unidentified O-glycosylation enzymes and their targets,
which can be linked to disease. 3D structural models of
human glycosyltransferases are rare, especially since
these types of proteins are embedded in the membrane
of the ER and Golgi apparatus making crystallization
extremely daunting. However, in recent years, some
structures have been resolved and modeled. Taken
together, new opportunities arise to link findings from
genetic disease with fundamental research to increase our
understanding of the mechanisms of O-glycosylation. In
this review, we illustrate the importance of inherited O-
glycosylation disorders to elucidate the structural aspects
of the O-glycosylation machinery (Figure 1). Glycosami-
noglycan biosynthesis disorders are not discussed and
have been described in great detail by others [21]. For
elaborate descriptions of O-glycosylation disorder pheno-
types, we recommend the reviews of Wopereis et al. [22],
Hennet [21] and Jaecken and Pe´anne [3].
O-glycosylation disorders: current status and
screening methods
Most of the currently known O-glycosylation disorders
have been identified through genetic techniques. The
clinical phenotypes are highly variable, which is linked to
the large number of different O-glycan types. O-glycosyl-
ation defects have now been identified for each type of O-
glycan, and an overview of the known O-glycosylation
disorders is provided in Figure 1 and Table 1. Thus far,
assays for functional validation of mutations are largely
lacking, except for the dystroglycanopathies. This is a
group of disorders affecting the O-mannosyl glycan on the
a-dystroglycan (aDG) protein that is essential for binding
to extracellular matrix components (Table 1; O-mannose).
Functional confirmation of O-mannosylation defects is
possible by histochemical detection of the O-mannosyl
glycan of aDG in muscle biopsies [23]. Together with
NGS of patients, this has resulted in the identification of
novel Golgi glycosyltransferases, while mass spectrome-
try of recombinant aDG has recently resolved the com-
plete O-mannose glycan structure [24,25,26].
Thus, together with NGS, functional tests are highly
warranted for a more rapid identification of inherited
O-glycosylation disorders, and to increase our understand-
ing of O-glycosylation mechanisms. O-glycomics, the
profiling of the complete set of glycans produced by
specific cell types, offers potential as a generic functional
test. Methods have been developed for the comparative
analysis of O-glycans from complex samples [27–30].
Unfortunately, O-glycomics has thus far not contributed
to the functional confirmation of O-glycosylation disor-
ders. This can be explained by the fact that O-glycosyla-
tion is highly dependent on the specific attachment site,
and O-glycans do not have a general consensus sequence
with the exception of O-fucose glycans (C2X3-5S/TC
3 and
WX5CX2/3S/TCX2G; C = conserved cysteines of epider-
mal growth factor (EGF)-like or TSRs, S/T = serine or
threonine, X = any residue) and O-glucose glycans
(C1XSXPC2). Therefore, it is essential to study O-glycan
structures in their protein context. Identification of aber-
rant O-glycopeptides by direct LC–MS/MS analysis of
intact O-glycopeptides in patient samples or model sys-
tems would be preferred, thus providing a complete
overview of the affected O-glycans and O-glycosylation
sites. Despite the challenges in the field of O-glycopro-
teomics (reviewed in Ref. [31]), first studies have dem-
onstrated the potential of LC–MS/MS for holistic O-
glycopeptide profiling. In 2016, Hoffmann et al. [32]
analyzed intact O-glycopeptides in human blood plasma
in an untargeted fashion by analyzing HILIC enriched
and fractionated glycopeptides by reversed phase LC–
MS/MS using multistage collision induced dissociation
(CID) and electron transfer dissociation (ETD) fragmen-
tation experiments. In total, 31 O-GalNAc sites and
regions from 22 proteins were identified, which included
11 novel O-glycosylation sites and regions. More recently,
King et al. [33] performed high collision energy dissoci-
ation (HCD) and ETD LC–MS/MS analysis of de-sialy-
lated glycopeptides purified by lectin chromatography
from AB RhD-positive platelets and blood plasma. Their
analysis detected 1123 O-GalNAc sites from 649 glyco-
proteins, which not only provided novel biological
insights but above all demonstrated the feasibility of
holistic O-glycoproteomics.
Although functional tests still need to be developed, the
O-glycosylation disorders that have been identified have
aided structural biology in a number of ways. Despite the
fact that O-glycan disorders are very heterogeneous,
patients generally show tissue-specific phenotypes, hint-
ing toward tissue-specific O-glycan targets and function.
Studying O-glycosylation disorders has 1) led to the
discovery of new glycosyltransferases and metabolic path-
ways, 2) provided insight in tissue-specific glycosylation
pathways, 3) aided in the discovery of O-glycosylation
targets and 4) elucidated structure-function relations
of O-glycosyltransferases and nucleotidyltransferases
(Figure 1). Below, we will provide recent examples of
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Characterization of O-glycosylation disorders is indispensable to accomplish a better understanding of the human O-glycosylation mechanisms.
Phenotypic heterogeneity of the O-glycosylation disorders reflects the high diversity of O-glycan structures with a high tissue-specificity.
Phenotypic characterization and modern omics techniques such as genomics, glycomics, and glycoproteomics complement each other in the
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each type of discovery in the O-glycosylation field, cov-
ering the majority of the O-glycosylation disorder core
types.
Discovery of new glycosyltransferases and metabolic
pathways
Firstly, genetic defects in O-glycosylation with a charac-
teristic phenotype have aided the discovery of new O-
glycosylation gene candidates. For example, NGS has
resulted in the identification of new genes causing dys-
troglycanopathy that is characterized by muscular dystro-
phy and, in severely affected individuals, eye and brain
abnormalities. Dystroglycanopathies are caused by defec-
tive O-mannosylation of aDG, leading to aberrant cell-to-
ECM connections. Genetic analysis of patients with
dystroglycanopathy features has revealed mutations in
ISPD (CRPPA), FKTN and TMEM5(RXYLT1) [34–37]
(Table 1; O-mannose). The function of these proteins
has been elucidated the last three years
[24,26,38,39,40]. Identification of ISPD as a cytosolic
cytidyltransferase even led to the discovery of a new
mammalian nucleotide sugar: CDP-ribitol [38]. Soon
after, FKTN and FKRP were identified as ribitol 5-
phosphate (Rbo5P) glycosyltransferases, and Rbo5P moi-
eties were detected on the functional O-mannosyl glycan
of aDG [24,26,39]. TMEM5 was identified as a b1,4-
xylosyltransferase, adding xylose onto the second Rbo5P
of unique O-mannosyl glycans on aDG [24,40]. Subse-
quently, mass spectrometry of genetically engineered
aDG led to the discovery of glycerol 3-phosphate (Gro3P)
on the glycan, indicating the existence of a CDP-glycerol
biosynthesis pathway [25]. This was further supported
by the finding that FKRP and FKTN can use CDP-
glycerol as substrates for glycosylation [41]. If CDP-
glycerol and Gro3P have a regulatory role in O-mannosyl
glycan extension remains to be investigated [25]. An
interesting observation is that these findings on aDG
show high overlap with the wall teichoic acids in gram-
positive bacteria, that contain repeating units of Rbo5P
and Gro3P [42]. The O-mannosylation disorders are a
classical example of how we learn about novel mecha-
nisms and even completely new human metabolic path-
ways, initiated by genetic screening of patients with
distinct O-glycosylation disorder phenotypes.
O-glycosylation disorders can provide insight in tissue-
specific pathways
Secondly, the phenotypes associated with O-glycosylation
disorders can provide important insights about tissue-
specific glycosylation mechanisms. This is nicely illus-
trated by POFUT1 (Table 1; O-fucose) and POGLUT1
(Table 1: O-glucose) deficiency, both resulting in Dowl-
ing-Degos disease. The shared phenotype, characterized
by reticular pigmentation of the skin [43,44], indicates a
similar underlying pathomechanism. Indeed, both
enzymes are involved in the regulation of Notch signal-
ing, however, by the addition of different glycan types.
POFUT1 stabilizes EGF-like repeats by the addition of
O-fucose glycans, and POGLUT1 through the addition of
O-glucose glycans [11]. Interestingly, POGLUT1 also
shows O-xylosyltransferase activity, but the function of O-
xylose on EGF-like domains remains to be investigated
[45,46]. The O-fucose glycan initiated by POFUT1 is
extended with N-acetylglucosamine (GlcNAc) by LNFG
[reviewed in Ref. 47]. Interestingly, LNFG patients pres-
ent with a completely different phenotype of vertebral
malsegmentation, spondylocostal dysostosis (SDO)
[48,49]. This phenotype is also associated with defects
in Notch signaling, and other types of SDO are all caused
by defects in proteins involved in Notch1 signaling [50].
Another recent article reports that the POGLUT1 D233E
mutation causes muscular dystrophy [51]. Investigating
other POGLUT1 targets could shed light on the mecha-
nisms underlying the different phenotypes. The different
phenotypes for POFUT1 and POGLUT1 deficiency pro-
vide opportunities to investigate tissue-specific targets
and O-glycosylation mechanisms.
Patient phenotypes aid in the identification of O-
glycosylation targets
The phenotype of some O-glycosylation deficiencies
resembles the phenotype of genetic defects in potential
target proteins. Hence, phenotypic characterizations can
point to potential glycosylation targets. For instance,
mutations in FGF23 cause familial tumoral calcinosis
paired with increased re-adsorption of phosphate by
the renal proximal tubule. Interestingly, patients carrying
mutations in the polypeptide GalNAc transferase
GALNT3 present with exactly the same phenotype [52–
57] (Table 1: O-GalNAc), suggesting a shared mechanism
of disease. Indeed, Kato et al. [13] demonstrated that the
phosphatonin FGF23 is O-glycosylated at Thr178 by
GALNT3, preventing the furin protease cleavage of
FGF23 and regulating phosphate re-absorption [13].
There are over 20 polypeptide GalNAc transferases.
Some share substrate specificities and have overlapping
expression in different tissues [6,7]. Nevertheless, O-
GalNAc glycosylation of FGF23 seems a non-redundant
function of GALNT3 [13]. Despite the large number of
GALNTs, only GALNT3 and GALNT2 deficiency have
been reported. Khetarpal et al. showed that loss of func-
tion of GALNT2 lowered high-density lipoprotein
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(Figure 1 Legend Continued) discovery of (tissue-specific) O-glycosylation transferases, pathways, targets and O-glycan function. Enzymes
causing known O-glycan disorders are in black. Enzymes in grey have not been associated with an O-glycosylation disorder. *Hypothesized
enzyme or multiple possible glycosyltransferases. GalNAc = N-acetylgalactosamine; GlcNAc = N-acetylglucosamine; Rbo = ribitol; P = phosphate. A
legend for the glycan symbols is presented in Table 1.
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cholesterol (HDL-C) levels in human, mice, rats and
cynomolgus monkeys. GALNT2 exhibited species-spe-
cific glycosylation targets, including PLTP, a regulator of
HDL metabolism in plasma [58]. PLTP activity was
altered by absence of GALNT2 O-GalNAc modifications,
explaining the findings in GALNT2 patients. The involve-
ment of additional GALNT2 targets in the disease phe-
notype remains to be investigated.
Likewise, mutations in OGT (O-GlcNAc-transferase) and
HCF1 (host cell factor 1, a transcriptional regulator of the
cell cycle) (cause similar intellectual disability (ID) phe-
notypes [59,60,61,62] (Table 1: O-GlcNAc). OGT is a
unique O-GlcNAc transferase that modifies nucleocyto-
plasmic proteins, a process that can be reversed by OGA
(O-GlcNAcase) [63–65]. All five patient mutations that
have been described so far reside in the N-terminal
tetratricopeptide (TPR) repeats of OGT, which are
involved in the substrate recognition and specificity of
OGT [66]. OGT patient-derived cells and model cell lines
with patient mutations showed normal O-GlcNAcylation
[59,60,62]. This homeostasis was suggested to be main-
tained by a reduced expression of OGA [59,60] or by
temporal dynamics in O-GlcNAcylation kinetics [62]. In
addition, OGT is involved in proteolytic maturation of
HCF1 [14,67], and it has been suggested that the
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Table 1
List of reported congenital O-glycosylation disorders with their associated OMIM numbers, phenotypes and method of diagnostics.
Affected glycan structures on serine or threonine (S/T) residues are given for each enzyme deficiency. Enzymes in black: reported
O-glycan defects. Enzymes in grey: no reported patients. *Hypothesized enzyme or multiple possible glycosyltransferases. **Putative
O-glycosylation disorders. LGMD = Limb-Girdle Muscular Dystrophy; MEB = Muscle Eye Brain disease; WWS = Walker-Warburg Syn-
drome; ID = Intellectual Disability. This table does not include the glycosaminoglycan biosynthesis disorders, or disorders known to
affect multiple glycosylation pathways, including O-glycosylation
O-GalNAc
Gene Function OMIM Disease Tissue Current diagnostics
GALNT2 Polypeptide GalNAc
transferase
602274 Reduced high-density
lipoprotein cholesterol
Brain Genetics, ApoC-III IEF
GALNT3 Polypeptide GalNAc
transferase
601756 Familial tumoral calcinosis Subcutaneous tissues, skin,
bone
Genetics
O-GlcNAc
Gene Function OMIM Disease Tissue Current diagnostics
OGT O-GlcNAc
transferase
proteolytic
processing
300255 X-linked ID Brain, skeleton, heart, face,
genitalia, eye
Genetics
EOGT EGF-domain-specific
O-GlcNAc
transferase
614789 Adams-Oliver syndrome Skin, skeleton Genetics
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O-Galactose
Gene Function OMIM Disease Tissue Current diagnostics
PLOD1 Helical lysyl
hydroxylase (LH1)
153454 Ehlers-Danlos syndrome,
kyphoscoliotic type, 1
Skeleton, skin,
muscle
Lysyl-protocollagen
hydroxylase activity in
skin fibroblasts,
genetics
PLOD2 Telopeptide lysyl
hydroxylase (LH2)
601865 Bruck-syndrome 2 Skeleton, skin Genetics
PLOD3 Lysyl hydroxylase/
hydroxylysyl
galactosyltransferase/
galactosylhydroxylysyl
glucosyltransferase (LH3)
603066 Lysyl hydroxylase
3 deficiency
Skeleton,
skin,
eye,
cochlea
or
auditory
nerve
Glucosyltransferase
activity in serum or
lymphoblastoid cells,
genetics
O-Glucose
Gene Function OMIM Disease Tissue Current diagnostics
POGLUT1 O-glucosyltransferase 615618 1) Dowling-Degos disease 4
2) Muscular dystrophy
1) Skin
2) Muscle
Genetics
O-Fucose
Gene Function OMIM Disease Tissue Current diagnostics
POFUT1 O-fucosyltransferase 607491 Dowling-Degos disease 2 Skin Genetics
LFNG O-fucose b-1,3-
GlcNAc transferase
602576 Spondylocostal Dysostosis 3 Axial skeleton Genetics, enzyme
activity assay
B3GLCT (B3GALTL) O-fucose b-1,3-
glucose transferase
610308 Peter’s Plus Syndrome Eye, face, skeleton,
lips
Genetics,
ELISA of
properdin serum
levels
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X-linked ID in some OGT patients is linked to insufficient
activated HCF1 [60]. Taken together, it is plausible that
ID genes are regulated or glycosylated by OGT, and this
should be addressed in further studies for a better under-
standing of the disease mechanisms.
For a long time, POMT1 and POMT2 were believed to
be the only human O-mannosyltransferases. In 2017,
glycoproteomics in HEK293 knock-out cells revealed
that the O-mannosylation of cadherins and protocadherins
is independent of these two enzymes [68]. Using a similar
approach, four new O-mannosyltransferases were identi-
fied. TMTC1-4, which specifically glycosylate cadherins
and protocadherins, and thus have different targets than
the POMT1/POMT2 glycosyltransferases (Table 1:
O-mannose) [68,69]. Interestingly, patients with
TMTC2 and TMTC3 mutations have very different phe-
notypes. TMTC3 mutations are associated with lissence-
phaly (6 families, 9 patients) and periventricular nodular
heterotopia with ID and epilepsy (three siblings) [70,71].
Both phenotypes are associated with deficient neuronal
migration. TMTC2 deficiency is associated with sensori-
neural hearing loss [72,73], suggesting that the TMTCs
have different, tissue-specific targets. Mutations in Cad-
herin-23 and Protocadherin-15 cause Usher syndrome,
which is characterized by deafness and blindness, and
can cause non-syndromic recessive hearing loss [74–76].
Hence, it is tempting to speculate that TMTC2 is
involved in the O-mannosylation of these proteins. How-
ever, direct demonstration of enzyme activity of the
TMTCs is still lacking and whether the TMTC3 and
TMTC2 disease phenotypes are directly related to
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O-Mannose
Gene Function OMIM Disease Tissue Current diagnostics
ISPD (CRPPA) CDP-ribitol synthase 614631 WWS, MEB, LGMD Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy
POMT1 Protein O-
mannosyltransferase
607423 WWS, MEB,LGMD Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy, O-
mannosyltransferase
activity assay
POMT2 Protein O-
mannosyltransferase
607439 WWS, MEB, LGMD Muscle, brain, eye, heart
POMK (SGK196) Protein O-mannosyl kinase 615247 WWS, MEB, LGMD Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy
POMGNT2 (GTDC2) O-mannose b-1,4-GlcNAc
transferase
614828 WWS Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy
B3GALNT2 b-GlcNAc b-1,3-GalNAc
transferase
610194 WWS, MEB, ID Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy
FKTN b-GalNAc-3 Rbo5P
transferase
607440 WWS, MEB, LGMD, FCMD Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy
FKRP Rbo5P-1 Rbo5P transferase 606596 WWS, MEB, LGMD Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy
TMEM5(RXYLT1) Rbo5P b-1,4-xylose
transferase
605862 WWS, MEB Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy
B4GAT1 xylose b-1,4-GlcA
transferase
605517 WWS Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy
LARGE a-xylose b-1,3-GlcA
transferase
b-GlcA a1,3-Xyl transferase
603590 WWS, MEB, LGMD Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy
POMGNT1 O-mannose b-1,2-GlcNAc
transferase
606822 WWS, MEB, LGMD,
nonsyndromic retinitis
pigmentosa
Muscle, brain, eye, heart Genetics, IIH6/VIA4-I on
muscle biopsy, O-Man
b-1,2 GlcNAc-
transferase activity assay
TMTC3** Putative O-
mannosyltransferase
617218 Cobblestone lissencephaly
Periventricular nodular
heterotopia
Brain, minimal muscle and
eye involvement
Genetics
TMTC2** Putative O-
mannosyltransferase
615856 Sensorineural hearing loss Cochlea or auditory nerve Genetics
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hypomannosylation of cadherins, protocadherins or other
proteins remains to be investigated.
Finally, B3GLCT deficiency leads to Peter’s Plus syn-
drome, a severe disorder characterized by anterior eye
chamber defects (Table 1: O-fucose). B3GLCT attaches
glucose via a b-1,3 linkage to O-fucose (synthesized by
POFUT2) on TSRs of proteins. In search for B3GLCT
targets linked to the eye defects, Dubail et al. [77] found
that ADAMTS9 haploinsufficient mice showed a similar
eye phenotype [77]. Glycosylation with glucose-b-1,3-
fucose by POFUT2 and B3GLCT ensures proper secre-
tion of ADAMTS9 during development. Taken together,
the identification of new genetic O-glycosylation disor-
ders can provide important insights about the targets and
functions of specific O-glycans.
Modeling mutations to study structure-function
relations of O-glycosylation proteins
In the last few years, crystal structures have been solved of
enzymes related to O-glycosylation disorders, for example of
OGT [78], POMK [79], POMGNT1 [80] and ISPD [38].
Known disease-causing mutations can be modeled in 3D
structures, helping to understand the function of specific
enzymatic domains and with it, underlying disease mecha-
nisms. For example, the crystal structure of ISPD revealed a
N-terminal cytidyltransferase domain and a C-terminal
domain connected via a linker helix [38]. Surprisingly, the
C-terminal domain did not share homology with any known
enzyme domains. No missense mutations have been
reported in the C-terminal domain, but the
c.1114_1116del (p.Val372del) mutation is reported for five
patients. The absence of the Val residue leads to relatively
mildphenotype(LGMD)comparedto largerdeletions likea
deletion of exon 6–8 or 9–10 (WWS). Taken together, this
demonstrates that the C-terminal domain is important for
ISPD function, either contributing to the stability of the
enzyme, or having a enzymatic function on its own [38], a
question that so far remains unanswered. For POMGNT1,
one study has reported a correlation between mutations
closer to the 50 end of the gene with more severe hydroceph-
alus than mutations near the 30 end. However, correlations
with enzymatic activity or structure have not been estab-
lished yet [81]. Taken together, much work remains to
elucidate the 3D structure of many O-glycosylation
enzymes. However, if such models are accomplished, struc-
ture-function relationships can be studied utilizing
described O-glycosylation patient mutations. Additionally,
this will lead to a better understanding of disease mecha-
nisms, and will hopefully be accompanied by the emergence
of new treatment opportunities.
Conclusions
We illustrated that studying the complex phenotypes of O-
glycosylation disorders has enabled the elucidation of O-
glycosylation proteins, targets, and O-glycan structure and
function. Nevertheless, many questions remain to be
answered about the O-glycosylation machinery. Although
we know in many diseases which O-glycan core structure is
affected, for most, their exact attachment site and tissue-
specific protein targets remain to be elucidated. In the
future, the development of more advanced O-glycopeptide
profiling methods is essential to facilitate these discoveries.
Ideally, untargeted O-glycoproteomics LC–MS/MS tech-
nology will evolve to enable robust high-throughput analy-
sis for the in-depth characterization of intact O-glycopep-
tides in biological samples. The screening of patient groups
with similar clinical presentations or with different genetic
O-glycosylation defects (e.g. in different GALNTs) with
genomics and O-glycoproteomics will lead to the discovery
of glycosylation genes and tissue-specific targets, respec-
tively. As illustrated in this review, comparing the pheno-
types of other known disorders to the phenotype of O-
glycosylation disorders can hint to the respective targets.
So far, most O-glycosylation defects that have been identi-
fied affect the core sugar of O-glycans. In the last few years,
NGS has been applied more frequently, and probably will
lead to the identification of additional disorders that affect
more distal monosaccharides on O-glycan structures. Func-
tional validation of these disorders will require develop-
ments in theglycoproteomicsfield, since large scale in-depth
characterization  of the exact glycan structure of intact gly-
copeptides is still challenging. Furthermore, it is important
to develop in-silico approaches to identify differential O-
glycopeptides and interpret complex glycobiology by novel
bioinformatic approaches. Combined analysis of O-glyco-
peptide data and patient meta data by machine learning is of
particular interest to associate protein specific O-glycosyla-
tion changes to the physiopathology of O-glycosylation dis-
orders. Taken together, understanding the disease mecha-
nisms of the O-glycosylation disorders will contribute to our
understanding of O-glycosylation mechanisms, while vice
versa, new mechanistic insights are highly warranted to
develop new therapeutic strategies.
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